XNYS · Healthcare · Drug Manufacturers - General
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson delivered a solid, low-drama beat in Healthcare, with **$2.90 EPS** and **$25.3B revenue** topping estimates and modestly improving YoY. Guidance of **$11.45-$11.65** EPS and **$100.3B-$101.3B** sales looks steady, but the quarter was more execution than catalyst.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-15 | Q2 2026 | 2.85 | 2.90 | +1.75% | $25.31B | ✅ Beat | +0.45% | — | — |
| 2026-04-14 | Q1 2026 | 2.67 | 2.70 | +1.12% | $24.06B | ✅ Beat | +0.23% | -5.81% | -3.87% |
| 2026-01-21 |
| Q4 2025 |
| 2.47 |
| 2.46 |
| -0.40% |
| $24.56B |
| ❌ Miss |
| -0.77% |
| +4.45% |
| +11.23% |
| 2025-10-14 | Q3 2025 | 2.76 | 2.80 | +1.45% | $23.99B | ✅ Beat | — | — | — |
| 2025-07-16 | Q2 2025 | 2.67 | 2.77 | +3.75% | $23.74B | ✅ Beat | — | — | — |
| 2025-04-15 | Q1 2025 | 2.60 | 2.77 | +6.54% | $21.89B | ✅ Beat | — | — | — |
| 2025-01-22 | Q4 2024 | 2.02 | 2.04 | +0.99% | $22.52B | ✅ Beat | — | — | — |
| 2024-10-15 | Q3 2024 | 2.21 | 2.42 | +9.50% | $22.47B | ✅ Beat | — | — | — |
Showing last 8 quarters.